Landos Biopharma Inc (LABP) USD0.01
$0.31
(1.40%)
- Add to watchlist
- This stock can be held in a
$0.31
(1.40%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.31
(1.40%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's disease (CD), that targets NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. It has several preclinical product candidates, including LABP-66, LABP-73 and LABP-69. LABP-73, an oral, small molecule NLRX1 agonist for the potential treatment of asthma and eosinophilic disorders.
Contact details
Important dates
General stock information
- Short code:
- LABP
- ISIN:
- US5150692011
- Market cap:
- $69.09 million
- Shares in issue:
- 3.12 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.